These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 37181352)
21. Mast cell activation disease and immunoglobulin deficiency in patients with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorder. Brock I; Prendergast W; Maitland A Am J Med Genet C Semin Med Genet; 2021 Dec; 187(4):473-481. PubMed ID: 34747107 [TBL] [Abstract][Full Text] [Related]
22. Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different? Aubry-Rozier B; Schwitzguebel A; Valerio F; Tanniger J; Paquier C; Berna C; Hügle T; Benaim C Rheumatol Int; 2021 Oct; 41(10):1785-1794. PubMed ID: 34398260 [TBL] [Abstract][Full Text] [Related]
23. Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Zoppi N; Chiarelli N; Binetti S; Ritelli M; Colombi M Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt A):1010-1023. PubMed ID: 29309923 [TBL] [Abstract][Full Text] [Related]
24. The Impact of Hypermobile "Ehlers-Danlos Syndrome" and Hypermobile Spectrum Disorder on Interpersonal Interactions and Relationships. De Baets S; De Temmerman M; Calders P; Malfait F; Van Hove G; Vanderstraeten G; De Wandele I; Van de Velde D Front Rehabil Sci; 2022; 3():832806. PubMed ID: 36188999 [TBL] [Abstract][Full Text] [Related]
25. Evaluation and Management of Dyspnea in Hypermobile Ehlers-Danlos Syndrome and Generalized Hypermobility Spectrum Disorder: Protocol for a Pilot and Feasibility Randomized Controlled Trial. Rozenberg D; Al Kaabi N; Camacho Perez E; Nourouzpour S; Lopez-Hernandez L; McGillis L; Goligher E; Reid WD; Chow CW; Ryan CM; Kumbhare D; Huszti E; Champagne K; Raj S; Mak S; Santa Mina D; Clarke H; Mittal N JMIR Res Protoc; 2023 Mar; 12():e44832. PubMed ID: 36939815 [TBL] [Abstract][Full Text] [Related]
26. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center. Ritelli M; Chiarelli N; Cinquina V; Vezzoli M; Venturini M; Colombi M Am J Med Genet A; 2024 Feb; 194(2):174-194. PubMed ID: 37774134 [TBL] [Abstract][Full Text] [Related]
27. Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know. Thwaites PA; Gibson PR; Burgell RE J Gastroenterol Hepatol; 2022 Sep; 37(9):1693-1709. PubMed ID: 35750466 [TBL] [Abstract][Full Text] [Related]
28. Bone parameters in hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: A comparative cross-sectional study. Coussens M; Banica T; Lapauw B; De Wandele I; Rombaut L; Malfait F; Calders P Bone; 2023 Jan; 166():116583. PubMed ID: 36243401 [TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal Symptoms in Marfan Syndrome and Hypermobile Ehlers-Danlos Syndrome. Inayet N; Hayat JO; Kaul A; Tome M; Child A; Poullis A Gastroenterol Res Pract; 2018; 2018():4854701. PubMed ID: 30151001 [TBL] [Abstract][Full Text] [Related]
30. Oral health-related quality of life among women with temporomandibular disorders and hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder. Yekkalam N; Sipilä K; Novo M; Reissmann D; Hanisch M; Oelerich O J Am Dent Assoc; 2024 Nov; 155(11):945-953. PubMed ID: 39352367 [TBL] [Abstract][Full Text] [Related]
31. Hypermobility spectrum disorders and active migraine in Israeli adolescents: A nationwide study. Zloof Y; Simchoni M; Derazne E; Tsur AM; Tzur D; Braun M; Amarilyo G; Shlaifer A; Honig A; Braun-Moscovici Y Headache; 2023; 63(7):934-941. PubMed ID: 37313588 [TBL] [Abstract][Full Text] [Related]
32. Childbearing with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: A Large International Survey of Outcomes and Complications. Pearce G; Bell L; Pezaro S; Reinhold E Int J Environ Res Public Health; 2023 Oct; 20(20):. PubMed ID: 37887695 [TBL] [Abstract][Full Text] [Related]
33. A randomised controlled trial of heavy shoulder strengthening exercise in patients with hypermobility spectrum disorder or hypermobile Ehlers-Danlos syndrome and long-lasting shoulder complaints: study protocol for the Shoulder-MOBILEX study. Liaghat B; Skou ST; Søndergaard J; Boyle E; Søgaard K; Juul-Kristensen B Trials; 2020 Dec; 21(1):992. PubMed ID: 33261635 [TBL] [Abstract][Full Text] [Related]
34. Co-Created Solutions for Perinatal Professionals and Childbearing Needs for People with Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders. Pearce G; Bell L; Magee P; Pezaro S Int J Environ Res Public Health; 2023 Oct; 20(20):. PubMed ID: 37887694 [TBL] [Abstract][Full Text] [Related]
35. Physical therapy interventions in generalized hypermobility spectrum disorder and hypermobile Ehlers-Danlos syndrome: a scoping review. Garreth Brittain M; Flanagan S; Foreman L; Teran-Wodzinski P Disabil Rehabil; 2024 May; 46(10):1936-1953. PubMed ID: 37231592 [TBL] [Abstract][Full Text] [Related]
36. Rectal hyposensitivity: a common pathophysiological finding in patients with constipation and associated hypermobile Ehlers-Danlos syndrome. Choudhary A; Vollebregt PF; Aziz Q; Scott SM; Fikree A Aliment Pharmacol Ther; 2022 Sep; 56(5):802-813. PubMed ID: 35758859 [TBL] [Abstract][Full Text] [Related]
37. Understanding hypermobile Ehlers-Danlos syndrome and Hypermobility Spectrum Disorders in the context of childbearing: An international qualitative study. Pezaro DS; Pearce DG; Reinhold DE Midwifery; 2020 Sep; 88():102749. PubMed ID: 32535291 [TBL] [Abstract][Full Text] [Related]
38. Bridging the Diagnostic Gap for Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Evidence of a Common Extracellular Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker. Ritelli M; Chiarelli N; Cinquina V; Bertini V; Piantoni S; Caproli A; Della Pina SEL; Franceschini F; Zarattini G; Gandy W; Venturini M; Zoppi N; Colombi M Am J Med Genet A; 2025 Jan; 197(1):e63857. PubMed ID: 39225014 [TBL] [Abstract][Full Text] [Related]
39. Defining a core outcome set for hypermobility spectrum disorders and hypermobile Ehlers-Danlos syndrome: A Delphi consensus study. Clark NL; Johnson M; Rangan A; Kottam L; Hogarth A; Scott S; Swainston K Clin Rheumatol; 2024 Dec; 43(12):3951-3961. PubMed ID: 39382742 [TBL] [Abstract][Full Text] [Related]
40. Subtle differences in autonomic symptoms in people diagnosed with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. Martinez KL; Mauss C; Andrews J; Saboda K; Huynh JM; Sanoja AJ; Jesudas R; Byers PH; Laukaitis CM Am J Med Genet A; 2021 Jul; 185(7):2012-2025. PubMed ID: 33826221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]